Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label tocilizumab trial in sepsis or septic shock
jRCT2051230173Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in sepsis and septic shock, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Pharmacodynamics - blood biomarkers and correlation with drug levels and Safety - adverse events and clinical safety parameters. Started Aug 2024; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on jRCT2051230173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230173.